vs
Side-by-side financial comparison of Hologic (HOLX) and Nextpower Inc. (NXT). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $909.4M, roughly 1.2× Nextpower Inc.). Hologic runs the higher net margin — 17.1% vs 14.4%, a 2.7% gap on every dollar of revenue. On growth, Nextpower Inc. posted the faster year-over-year revenue change (33.9% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $118.5M). Over the past eight quarters, Nextpower Inc.'s revenue compounded faster (11.1% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Nextpower Inc. (NXT) is a global energy technology provider based in Fremont, California.
HOLX vs NXT — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $909.4M |
| Net Profit | $179.1M | $131.2M |
| Gross Margin | 56.0% | 31.7% |
| Operating Margin | 22.6% | 19.4% |
| Net Margin | 17.1% | 14.4% |
| Revenue YoY | 2.5% | 33.9% |
| Net Profit YoY | -10.9% | 13.8% |
| EPS (diluted) | $0.79 | $0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $909.4M | ||
| Q3 25 | $1.0B | $905.3M | ||
| Q2 25 | $1.0B | $864.3M | ||
| Q1 25 | $1.0B | $924.3M | ||
| Q4 24 | $1.0B | $679.4M | ||
| Q3 24 | $988.0M | $635.6M | ||
| Q2 24 | $1.0B | $719.9M | ||
| Q1 24 | $1.0B | $736.5M |
| Q4 25 | $179.1M | $131.2M | ||
| Q3 25 | $187.2M | $146.9M | ||
| Q2 25 | $194.9M | $157.2M | ||
| Q1 25 | $-17.4M | $156.8M | ||
| Q4 24 | $201.0M | $115.3M | ||
| Q3 24 | $178.6M | $115.4M | ||
| Q2 24 | $194.5M | $121.7M | ||
| Q1 24 | $169.9M | $205.2M |
| Q4 25 | 56.0% | 31.7% | ||
| Q3 25 | 55.6% | 32.4% | ||
| Q2 25 | 56.3% | 32.6% | ||
| Q1 25 | 37.5% | 33.1% | ||
| Q4 24 | 56.8% | 35.5% | ||
| Q3 24 | 56.4% | 35.4% | ||
| Q2 24 | 55.4% | 33.0% | ||
| Q1 24 | 53.3% | 46.2% |
| Q4 25 | 22.6% | 19.4% | ||
| Q3 25 | 22.6% | 20.0% | ||
| Q2 25 | 24.9% | 21.5% | ||
| Q1 25 | -0.7% | 21.1% | ||
| Q4 24 | 22.5% | 22.1% | ||
| Q3 24 | 23.3% | 21.0% | ||
| Q2 24 | 24.1% | 22.2% | ||
| Q1 24 | 20.7% | 36.8% |
| Q4 25 | 17.1% | 14.4% | ||
| Q3 25 | 17.8% | 16.2% | ||
| Q2 25 | 19.0% | 18.2% | ||
| Q1 25 | -1.7% | 17.0% | ||
| Q4 24 | 19.7% | 17.0% | ||
| Q3 24 | 18.1% | 18.2% | ||
| Q2 24 | 19.2% | 16.9% | ||
| Q1 24 | 16.7% | 27.9% |
| Q4 25 | $0.79 | $0.85 | ||
| Q3 25 | $0.84 | $0.97 | ||
| Q2 25 | $0.86 | $1.04 | ||
| Q1 25 | $-0.08 | $1.05 | ||
| Q4 24 | $0.87 | $0.79 | ||
| Q3 24 | $0.75 | $0.79 | ||
| Q2 24 | $0.82 | $0.84 | ||
| Q1 24 | $0.72 | $1.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $952.6M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $2.2B |
| Total Assets | $9.2B | $3.8B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $952.6M | ||
| Q3 25 | $2.2B | $845.3M | ||
| Q2 25 | $1.9B | $743.4M | ||
| Q1 25 | $1.6B | $766.1M | ||
| Q4 24 | $2.0B | $693.5M | ||
| Q3 24 | $2.3B | $561.9M | ||
| Q2 24 | $2.4B | $471.9M | ||
| Q1 24 | $2.2B | $474.1M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | $2.2B | ||
| Q3 25 | $5.0B | $2.0B | ||
| Q2 25 | $4.8B | $1.8B | ||
| Q1 25 | $4.6B | $1.6B | ||
| Q4 24 | $4.8B | $1.4B | ||
| Q3 24 | $5.1B | $1.3B | ||
| Q2 24 | $5.0B | $1.1B | ||
| Q1 24 | $4.8B | $961.0M |
| Q4 25 | $9.2B | $3.8B | ||
| Q3 25 | $9.0B | $3.7B | ||
| Q2 25 | $8.8B | $3.4B | ||
| Q1 25 | $8.5B | $3.2B | ||
| Q4 24 | $8.7B | $3.0B | ||
| Q3 24 | $9.2B | $2.8B | ||
| Q2 24 | $8.9B | $2.6B | ||
| Q1 24 | $8.7B | $2.5B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $123.3M |
| Free Cash FlowOCF − Capex | $215.2M | $118.5M |
| FCF MarginFCF / Revenue | 20.5% | 13.0% |
| Capex IntensityCapex / Revenue | 1.4% | 0.5% |
| Cash ConversionOCF / Net Profit | 1.28× | 0.94× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $587.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $123.3M | ||
| Q3 25 | $355.1M | $186.9M | ||
| Q2 25 | $343.3M | $81.3M | ||
| Q1 25 | $169.4M | $237.3M | ||
| Q4 24 | $189.3M | $143.8M | ||
| Q3 24 | $367.0M | $153.8M | ||
| Q2 24 | $405.8M | $120.8M | ||
| Q1 24 | $292.4M | $111.5M |
| Q4 25 | $215.2M | $118.5M | ||
| Q3 25 | $341.4M | $171.4M | ||
| Q2 25 | $330.5M | $70.1M | ||
| Q1 25 | $153.9M | $227.2M | ||
| Q4 24 | $172.5M | $134.9M | ||
| Q3 24 | $350.6M | $141.8M | ||
| Q2 24 | $385.3M | $118.0M | ||
| Q1 24 | $279.6M | $109.2M |
| Q4 25 | 20.5% | 13.0% | ||
| Q3 25 | 32.5% | 18.9% | ||
| Q2 25 | 32.3% | 8.1% | ||
| Q1 25 | 15.3% | 24.6% | ||
| Q4 24 | 16.9% | 19.9% | ||
| Q3 24 | 35.5% | 22.3% | ||
| Q2 24 | 38.1% | 16.4% | ||
| Q1 24 | 27.5% | 14.8% |
| Q4 25 | 1.4% | 0.5% | ||
| Q3 25 | 1.3% | 1.7% | ||
| Q2 25 | 1.3% | 1.3% | ||
| Q1 25 | 1.5% | 1.1% | ||
| Q4 24 | 1.6% | 1.3% | ||
| Q3 24 | 1.7% | 1.9% | ||
| Q2 24 | 2.0% | 0.4% | ||
| Q1 24 | 1.3% | 0.3% |
| Q4 25 | 1.28× | 0.94× | ||
| Q3 25 | 1.90× | 1.27× | ||
| Q2 25 | 1.76× | 0.52× | ||
| Q1 25 | — | 1.51× | ||
| Q4 24 | 0.94× | 1.25× | ||
| Q3 24 | 2.05× | 1.33× | ||
| Q2 24 | 2.09× | 0.99× | ||
| Q1 24 | 1.72× | 0.54× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
NXT
| Transferred Over Time | $763.9M | 84% |
| Transferred At Point In Time | $145.4M | 16% |
